Vector for expressing target protein comprising calsequestrin domain as fusion partner and method for producing target protein using same
By employing specific CSQ domains as fusion partners, the challenges of large molecular weight CSQ are overcome, leading to increased expression and simplified purification of recombinant proteins.
Patent Information
- Application Number
- PCT/KR2026/006000
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-12
- Filing Date
- 2026-05-12
- Publication Date
- 2026-11-19
AI Technical Summary
The large molecular weight of calsequestrin (CSQ) leads to reduced production efficiency and complexity in the purification process of recombinant proteins, making it difficult for mass production and commercialization.
Using specific domains of CSQ, such as CSQ Domain 1, Domain 2, Domain 3, or combinations thereof, as fusion partners with a target protein, reducing the overall molecular weight while maintaining high expression efficiency and stability.
Enhances protein expression levels and simplifies purification processes, improving overall protein production efficiency and commercial viability.
Smart Images

Figure KR2026006000_19112026_PF_FP_ABST
Abstract
Description
Vector for expressing a target protein containing a calsequestrin domain as a fusion partner and a method for producing a target protein using the same
[0001] The present invention relates to a vector for expressing a target protein comprising a calsequestrin domain as a fusion partner and a method for producing a target protein using the same.
[0002] Among them, calsequestrin (CSQ) has been widely used as a fusion partner due to its excellent expression efficiency, protein stability, and durability in high-temperature and high-salt environments. CSQ plays an important role in intracellular calcium storage and regulation, and thanks to these characteristics, it can contribute to enhancing the expression and stability of recombinant proteins.
[0003]
[0004] However, since the molecular weight of CSQ is relatively large at approximately 43 kDa, the size of the target protein fused with it becomes large. This can lead to a decrease in the production efficiency of the recombinant protein or cause unnecessary complexity in the subsequent purification process. Additionally, due to the large size of CSQ, separation from the target protein may become difficult, which can be a practical problem for mass production and commercialization.
[0005]
[0006] To address these issues, it is necessary to develop new fusion partners capable of reducing molecular weight while maximally preserving the functional properties of calsequestrin. This would enable increased protein expression efficiency while minimizing problems during the purification process, thereby laying the foundation for more efficient protein production and commercialization.
[0007]
[0008] Prior art
[0009] Republic of Korea Published Patent No. 10-2020-0117881 (October 14, 2020)
[0010] The present invention aims to provide an improved fusion partner that can improve the expression level and productivity of a target protein by reducing its molecular weight while maintaining the advantages of the existing calsequestrin (CSQ) protein.
[0011]
[0012] The inventors confirmed that when only some of the three domains constituting the calsequestrin (CSQ) protein are used as fusion partners, the expression level of the fused target protein increases compared to when the entire CSQ protein is used. In particular, the domain defined by the following sequence was used as the fusion partner.
[0013] CSQ Domain 1: Sequence Number 1
[0014] CSQ Domain 2: Sequence No. 2
[0015] CSQ Domain 3: Sequence Number 3
[0016] CSQ Domain 1 and Domain 2: Sequence No. 4
[0017] CSQ Domain 1 and Domain 3: Sequence No. 5
[0018] CSQ domain 2 and domain 3: SEQ ID NO. 6. The vector according to the present invention is configured such that at least one CSQ domain sequence among SEQ ID NOs 1 to 6 is fused to the N-terminus or C-terminus of the target protein, and can exhibit higher expression efficiency than when using the entire CSQ protein (SEQ ID NO. 7).
[0019]
[0020] However, the problems that this invention seeks to solve are not limited to those mentioned above, and other unmentioned problems will be clearly understood by those skilled in the art from the description below.
[0021] The present invention aims to provide a vector for expressing a target protein comprising a calsequestrin (CSQ) domain as a fusion partner, and a method for producing a target protein using the same.
[0022]
[0023] According to one embodiment,
[0024] The present invention aims to provide a vector for expressing a target protein comprising a calsequestrin (CSQ) domain as a fusion partner. Herein, the calsequestrin domain is characterized by being composed of an amino acid sequence selected from the group consisting of SEQ ID NOs 1 to 6.
[0025] In the present invention, the target protein may be one or more selected from the group consisting of high molecular weight proteins, peptides, glycoproteins, cytokines, growth factors, blood products, vaccines, hormones, enzymes, antibodies, and synthetic preparations.
[0026] In the present invention, the vector may include a linker sequence between the calsequestrin domain and the target protein. The linker sequence may be one or more of GGGGS, GSGSGS, or (GGGGS)n (n=1 to 10) repeat sequences.
[0027] In the present invention, the vector may include a cleavage site between the calsequestrin domain and the target protein. The cleavage site may be one or more of a thrombin recognition sequence (LVPRGS), an enterokinase recognition sequence (DDDDK), a TEV protease recognition sequence (ENLYFQG), or a factor Xa recognition sequence (IEGR).
[0028]
[0029] According to another embodiment,
[0030] The present invention comprises the step of A) preparing an expression vector comprising a nucleic acid encoding a fusion protein in which a calsequestrin domain and a target protein are fused through a cleavage site;
[0031] B) A step of obtaining a transformant by introducing the above expression vector into a host cell;
[0032] C) A step of expressing a fusion protein in which a calsequestrin domain and a target protein are fused from the above transformant;
[0033] D) a step of precipitating a fusion protein from the expressed transformant using calcium; and
[0034] E) A step of separating the target protein from the fusion protein using a hydrolytic enzyme;
[0035] The present invention provides a method for producing a target protein using a calciquestrin domain comprising: the calciquestrin domain comprising the above. The calciquestrin domain is characterized by being composed of an amino acid sequence selected from the group consisting of SEQ ID NOs 1 to 6.
[0036] According to the vector containing the calsequestrin (CSQ) domain of the present invention, it has been demonstrated that when the calsequestrin domain is used as a fusion partner for the target protein, the expression level of the target protein can be significantly increased compared to when the entire calsequestrin is used.
[0037]
[0038] Furthermore, since the CSQ domain has a smaller molecular weight compared to the entire CSQ, it can reduce the total molecular weight of the fusion protein, which can lead to improved productivity. Consequently, efficiency is expected in the protein expression and purification processes.
[0039]
[0040] Meanwhile, the scope of the rights of the present invention is not limited by the effects mentioned above.
[0041] Figure 1 shows the results of comparing the expression effect when the target protein according to Example 1 is fused with CSQ or a CSQ domain.
[0042] Figure 2 shows the results of comparing the expression effect when the target protein according to Example 2 is fused with CSQ or D1.
[0043] Figure 3 shows the results of comparing the expression effect when the target protein according to Example 3 is fused with CSQ or D1-D2.
[0044] Figure 4 shows the results of comparing the expression effect when the target protein according to Example 4 is fused with CSQ or D1-D3.
[0045] Figure 5 shows the results of comparing the effect of target protein expression in mammalian cells when the target protein according to Example 5 is fused with CSQ and D1-D2.
[0046] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as generally understood by those skilled in the art to which this disclosure pertains. Any method, material, composition, reagent, or cell similar or equivalent to that described herein may be used to carry out or test the subject matter of this disclosure, but preferred methods and materials are described. All publications and references, including but not limited to patents and patent applications cited herein, are incorporated herein by reference in their entirety as indicated, so that each individual publication or reference is incorporated herein by reference in its entirety as specifically and individually presented. Any patent application for which this application claims priority is also incorporated herein by reference in its entirety in the manner described above with respect to publications and references.
[0047] As used herein, the term "amino acid" refers to both natural and non-natural amino acids, as well as amino acid analogs and mimics. Natural amino acids include 20(L)-amino acids used during protein biosynthesis, as well as others such as, for example, 4-hydroxyproline, hydroxylysine, desmosine, isodesmosine, homocysteine, citrulline, and ornithine. Non-natural amino acids include, for example, (D)-amino acids, norleucine, norvaline, p-fluorophenylalanine, ethionine, etc., which are known to those skilled in the art. Amino acid analogs include modified forms of natural and non-natural amino acids. Such modifications may include, for example, the substitution or replacement of chemical groups and moiety on the amino acid, or the derivatization of the amino acid. Amino acid mimics include organic structures that exhibit functionally similar properties, such as the charge and charge spacing characteristics of the reference amino acid, for example. For example, an organic structure mimicking arginine (Arg or R) will have a positively charged moiety located in a similar molecular space and having the same degree of mobility as the e-amino group of the side chain of the natural Arg amino acid. The mimic also includes a structure forced to maintain optimal spacing and charge interactions of the amino acid or amino acid functional group. A person skilled in the art may know or determine the structures constituting functionally equivalent amino acid analogs and amino acid mimics.
[0048] As used herein, the terms “polypeptide,” “protein,” and “peptide” are used interchangeably and refer to a polymer of amino acids not limited to any specific length. The term “polypeptide” or “protein” refers to a chain of one or more amino acids, wherein each chain comprises amino acids covalently linked by peptide bonds, and said polypeptide or protein may comprise a plurality of chains non-covalently and / or covalently linked together by peptide bonds having a sequence of a natural protein, i.e., a natural and specifically non-recombinant cell, or a protein produced by a genetically engineered or recombinant cell, and may comprise a molecule having an amino acid sequence of a natural protein, or a molecule having a deletion, addition, and / or substitution thereof from one or more amino acids of the natural sequence. In certain embodiments, the polypeptide is a “recombinant” polypeptide produced by a recombinant cell comprising one or more recombinant DNA molecules, which typically consists of a heterogeneous polynucleotide sequence or a combination of polynucleotide sequences that would not otherwise be found in the cell.
[0049] As used herein, the terms “polynucleotide” and “nucleic acid” include mRNA, RNA, cRNA, cDNA, and DNA. The terms refer to polymeric forms of nucleotides having a length of at least 10 bases, typically ribonucleotides or deoxynucleotides or modified forms of either type of nucleotide. The terms include DNA in single and double-stranded forms. The terms “isolated DNA,” “isolated polynucleotide,” and “isolated nucleic acid” refer to molecules isolated without the whole genomic DNA of a particular species. Thus, an isolated DNA segment encoding a polypeptide refers to a DNA segment that contains one or more coding sequences but is substantially isolated or purified from the whole genomic DNA of the species from which the DNA segment is obtained. Additionally, non-coding polynucleotides that do not encode polypeptides (e.g., primers, probes, oligonucleotides) are included. Additionally, recombinant vectors are included, for example, expression vectors, viral vectors, plasmids, cosmids, phages, viruses, etc.
[0050] As used in this specification, the term “fusion” refers to a form in which two or more proteins are artificially linked, and in the present invention, it refers to a protein in which calciquestrin is linked to a bioactive substance. Such a fusion protein may be obtained by chemically conjugating or by expressing and purifying it using a genetic recombination method. There are no specific restrictions on the linkage order of calciquestrin and the bioactive substance in the fusion protein, and it may include both “terminus - calciquestrin - target protein - C-terminus” and “terminus - target protein - calciquestrin - C-terminus” forms.
[0051]
[0052] 1. Vector
[0053] The present invention aims to provide a vector for expressing a target protein comprising a calsequestrin (CSQ) domain as a fusion partner. The vector may include a calsequestrin domain and a nucleic acid encoding a target protein. In the present invention, the calsequestrin domain is characterized by being composed of an amino acid sequence selected from the group consisting of SEQ ID NOs 1 to 6.
[0054] In the vector according to the present invention, the calciquestrin domain may consist of the amino acid sequence of SEQ ID NO. 1.
[0055] In the vector according to the present invention, the calciquestrin domain may consist of the amino acid sequence of SEQ ID NO. 4.
[0056] In the vector according to the present invention, the calciquestrin domain may consist of the amino acid sequence of SEQ ID NO. 5.
[0057] In the vector according to the present invention, the target protein may be one or more selected from the group consisting of high molecular weight proteins, peptides, glycoproteins, cytokines, growth factors, blood products, vaccines, hormones, enzymes, antibodies, and synthetic preparations. For example, the above bioactive substances are Interleukin-2, blood factor VII, blood factor VIII, blood factor IX, immunoglobulin, horseradish peroxidase (HRP), cytokine, α-interferon, β-interferon, γ-interferon, colony-stimulating factor (GM-CSF), human fibronectin extra domain B (EBD), fibroblast growth factor (FGF), nerve growth factor (NGF), insulin-like growth factor (IGF), transforming growth factor (trans-forming growth factor-α and -β, TGF-α, -β). Brain-derived neutrophic factor (BDNF), platelet-derived growth factor (PDGF), placental growth factor (PlGF), hepatocyte growth factor (HGF), Exendin, somatostatin, LHRH (luteinizing hormone-releasing hormone), adrenocorticotropic hormone, growth hormone-releasing hormone, oxytocin, thymosin alpha-1, corticotropin-releasing factor, calcitonin,Bivalirudin, vasopressin, phospholipase-activated protein (PLAP), insulin, tumor necrosis factor (TNF), vesicle-stimulating hormone, thyroid-stimulating hormone, antidiuretic hormone, chromosomal hormone, parathyroid hormone, luteinizing hormone, calcitonin gene-related peptide (CGPR), enkephalin, somatomedin, erythropoietin, hypothalamic-secreted factor, prolactin, chronic gonadotropin, tissue plasminogen activator, growth hormone releasing peptide (GHPR), thymic humoral factor (THF), asparaginase, arginase, arginine deaminase, adenosine deaminase, superoxide dismutase, endotoxinase, Catalase, Chymotrypsin, Lipase, Uricase, Adenosine Diphosphatase, Tyrosinase, Bilirubin Oxidase, Glucose Oxidase, Glucodase, Galactosidase, Glucocerebrosidase, Glucouronidase, Keratinocyte Growth Factor (KGF), Exenatide, Doxorubicin, Anti-VEGF scFv, SARS-Cov2 RBD (receptor binding domain), Epidermal Growth Factor (EGF), Fibroblast Growth Factor-2, Bone Morphogenetic Protein (BMP2), Transforming Growth Factor, Vascular Endothelial Growth Factor (VEGF), Glucagon-like Peptide-1 (glucagon-like peptide-1, GLP-1),It may be one or more selected from the group consisting of TEV protease, HRP enzyme, human growth hormone (hGH), and hematopoietic growth factor (G-CSF), but is not limited thereto. According to one exemplary embodiment, GFP, hGH, Protein-G, Protein-A, Ag85b, M201, and M301 were used as the target proteins.
[0058] In a vector according to the present invention, the vector may include a linker sequence between a calsequestrin domain and a target protein. The linker sequence may be one or more of GGGGS, GSGSGS, or (GGGGS)n (n=1 to 10) repeat sequences.
[0059] In a vector according to the present invention, the vector may include a cleavage site between a calciquestrin domain and a target protein. The cleavage site may be one or more of a thrombin recognition sequence (LVPRGS), an enterokinase recognition sequence (DDDDK), a TEV protease recognition sequence (ENLYFQG), or a factor Xa recognition sequence (IEGR).
[0060] In the vector according to the present invention, the target protein may exhibit a higher expression level than the target protein containing SEQ ID NO. 7 as a fusion partner.
[0061]
[0062] 2. Method for producing the target protein
[0063] The present invention
[0064] A) A step of preparing an expression vector comprising a nucleic acid encoding a fusion protein in which a calsequestrin domain and a target protein are fused through a cleavage site;
[0065] B) A step of obtaining a transformant by introducing the above expression vector into a host cell;
[0066] C) A step of expressing a fusion protein in which a calsequestrin domain and a target protein are fused from the above transformant;
[0067] D) a step of precipitating a fusion protein from the expressed transformant using calcium; and
[0068] E) A step of separating the target protein from the fusion protein using a hydrolytic enzyme;
[0069] The present invention aims to provide a method for producing a target protein using a calciquestrin domain comprising: a calciquestrin domain comprising a calciquestrin domain. In the present invention, the calciquestrin domain is characterized by being composed of an amino acid sequence selected from the group consisting of SEQ ID NOs 1 to 6.
[0070] In the method for producing a target protein according to the present invention, the calciquestrin domain may be composed of the amino acid sequence of SEQ ID NO. 1.
[0071] In the method for producing a target protein according to the present invention, the calciquestrin domain may be composed of the amino acid sequence of SEQ ID NO. 4.
[0072] In the method for producing a target protein according to the present invention, the calciquestrin domain may be composed of the amino acid sequence of SEQ ID NO. 5.
[0073] In the method for producing a target protein according to the present invention, the calcium used in step (d) is not particularly limited as long as it is a substance capable of providing calcium ions, and may be, for example, calcium chloride (CaCl₂), calcium sulfate (CaSO₄), calcium nitrate (Ca(NO₃)₂), or calcium acetate (Ca(CH₃COO)₂).
[0074] In the method for producing a target protein according to the present invention, the target protein may be one or more selected from the group consisting of high molecular weight proteins, peptides, glycoproteins, cytokines, growth factors, blood products, vaccines, hormones, enzymes, antibodies, and synthetic preparations. For example, the above bioactive substances are Interleukin-2, blood factor VII, blood factor VIII, blood factor IX, immunoglobulin, horseradish peroxidase (HRP), cytokines, α-interferon, β-interferon, γ-interferon, colony-stimulating factor (GM-CSF), human fibronectin extra domain B (EBD), fibroblast growth factor (FGF), nerve growth factor (NGF), insulin-like growth factor (IGF), transforming growth factor (trans-forming growth factor-α and -β, TGF-α, -β), brain-derived neutrophic factor (BDNF), platelet-derived growth factor (PDGF), placental growth factor (PlGF), Hepatocyte growth factor (HGF), Exendin, somatostatin, LHRH (luteinizing hormone-releasing hormone), adrenocorticotropic hormone, growth hormone-releasing hormone, oxytocin, thymosin alpha-1, corticotropin-releasing factor,Calcitonin, bivalirudin, vasopressin, phospholipase-activated protein (PLAP), insulin, tumor necrosis factor (TNF), vesicle-stimulating hormone, thyroid-stimulating hormone, antidiuretic hormone, chromogenic hormone, parathyroid hormone, luteinizing hormone, calcitonin gene-related peptide (CGPR), enkephalin, somatomedin, erythropoietin, hypothalamic-secreted factor, prolactin, chronic gonadotropin, tissue plasminogen activator, growth hormone releasing peptide (GHPR), thymic humoral factor (THF), asparaginase, arginase, arginine deaminase, adenosine deaminase, peroxide dismutase, Endotoxinase, catalase, chymotrypsin, lipase, uricase, adenosine diphosphatase, tyrosinase, bilirubin oxidase, glucose oxidase, glucodase, galactosidase, glucocerebrosidase, glucouronidase, keratinocyte growth factor (KGF), exenatide, doxorubicin, anti-vascular endothelial growth factor (Anti-VEGF scFv), SARS-Cov2 RBD (receptor binding domain), epidermal growth factor (EGF), fibroblast growth factor-2, bone morphogenetic protein (BMP2), transforming growth factor, vascular endothelial growth factor (VEGF),It may be one or more selected from the group consisting of glucagon-like peptide-1 (GLP-1), TEV protease, HRP enzyme, human growth hormone (hGH), and hematopoietic growth factor (G-CSF), but is not limited thereto. According to one exemplary embodiment, GFP, hGH, Protein-G, Protein-A, Ag85b, M201, and M301 were used as the target proteins.
[0075] In a method for producing a target protein according to the present invention, the vector may include a linker sequence between the calciquestrin domain and the target protein. The linker sequence may be one or more of GGGGS, GSGSGS, or (GGGGS)n (n=1 to 10) repeat sequences.
[0076] In a method for producing a target protein according to the present invention, the vector may include a cleavage site between the calciquestrin domain and the target protein. The cleavage site may be one or more of a thrombin recognition sequence (LVPRGS), an enterokinase recognition sequence (DDDDK), a TEV protease recognition sequence (ENLYFQG), or a factor Xa recognition sequence (IEGR).
[0077] In the method for producing a target protein according to the present invention, the host cell may be one or more selected from the group consisting of Escherichia coli, Bacillus subtilis, Bacillus churingensis, Salmonella typhimurium, Serratia marcescens, Pseudomonas species, yeast, insect cells, CHO cell line (Chinese hamster ovary), W138, BHK, COS-7, 293, HepG2, 3T3, RIN, MDCK cell line, and plant cells.
[0078] In the method for producing a target protein according to the present invention, the target protein may exhibit a higher expression level than a target protein containing SEQ ID NO. 7 as a fusion partner.
[0079] Various embodiments are presented below to aid in understanding the invention. The following embodiments are provided merely to facilitate a better understanding of the invention and do not limit the scope of protection of the invention to the following embodiments.
[0080]
[0081] <Example>
[0082] Example 1: Comparison of CSQ and expression of each domain
[0083] Figure 1 shows the results of expression experiments for the entire CSQ protein (SEQ ID NO. 7), individual domains (D1: SEQ ID NO. 1, D2: SEQ ID NO. 2, D3: SEQ ID NO. 3), and domain combinations (D1 and D2: SEQ ID NO. 4, D1 and D3: SEQ ID NO. 5, D2 and D3: SEQ ID NO. 6). pET28a was used as the expression vector, and BL21(DE3) was used as the E. coli host. As a result of analyzing the proteins expressed after IPTG induction using SDS-PAGE and GelAnalyzer ver 26.1 software, it was confirmed that D1, D1-D2, and D1-D3 could exhibit higher expression compared to the entire CSQ (SEQ ID NO. 7).
[0084]
[0085] Example 2. Comparison of target protein expression using CSQ and D1 domains as fusion partners
[0086] Figure 2 compares the expression results when GFP, hGH, Protein-G, and Protein-A are fused to SEQ No. 1 or SEQ No. 7. It was confirmed that for all target proteins, the case where SEQ No. 1 (CSQ domain 1) is fused can show a higher expression level than the case where the entire CSQ (SEQ No. 7) is fused.
[0087]
[0088] Example 3. Comparison of target protein expression using CSQ and D1-D2 fusion domains
[0089] Figure 3 shows the expression experiment in which Ag85b, Protein-G, tuberculosis antigen M201, and tuberculosis antigen M301 were fused to SEQ No. 4 or SEQ No. 7. It was confirmed that for all target proteins, the fusion of SEQ No. 4 (CSQ domains 1 and 2) could show a higher expression level than SEQ No. 7 (the entire CSQ).
[0090]
[0091] Example 4. Comparison of target protein expression using CSQ and D1-D3 fusion domains
[0092] Figure 4 shows the expression experiment when GFP, hGH, Protein-G, and Ag85b are fused to SEQ No. 5 or SEQ No. 7. It was confirmed that in the case of fusion of SEQ No. 5 (CSQ domains 1 and 3), a higher expression level can be exhibited than with the total CSQ fusion.
[0093]
[0094] Example 5. Comparison of target protein expression using CSQ D1-D2 fusion domain
[0095] Figure 5 shows that an expression vector was prepared by inserting recombinant DNA consisting of 6x histidine-sequence number 4 (CSQ domains I and II)-minibody antibody genes below the secretion signal sequence of the pCDNA3.4 vector. After transforming CHO-S (suspension cell type) cells using PEI (polyethyleneimine), they were cultured for 48 hours in 100 ml of ExpiCHO Expression Medium (Thermo Fisher) at 37°C under 5% CO2 conditions.
[0096] The secreted fusion protein was purified from the obtained culture medium using an open column packed with Ni-NTA agarose resin (Fig. 5). The process of purifying the histidine tag fusion protein using Ni-NTA agarose resin was no different from a general protocol.
[0097] As shown in Figure 5, it was confirmed that the fusion protein was expressed at a high level and secreted into the culture medium, which means that the CSQ domain fusion protein can be effectively produced in mammalian cells as well.
[0098]
[0099] Specific parts of the present invention have been described in detail above. It is evident to those skilled in the art that such specific descriptions are merely preferred embodiments and do not limit the scope of the invention. Accordingly, the actual scope of the invention is defined by the appended claims and their equivalents.
[0100]
[0101] Research Project Information:
[0102] [Project ID] 2420027467
[0103] [Ministry Name] Ministry of SMEs and Startups
[0104] [Specialized Research Management Agency] Korea Technology Information Promotion Agency for SMEs
[0105] [Research Project Name] Startup Growth Technology Development Project
[0106] [Research Project Title] Development of EasyTag-based Production Process for Non-expressing Proteins Service
[0107] [Organizing Organization] ToolBio
[0108]
[0109] [Sequence No. 1] CSQ domain 1 amino acid sequence
[0110] QEGLDFPEYDGVDRVINVNAKNYKNVFKKYEVLALLYHEPPEDDKASQRQFEMEELILELAAQVLEDKGVGFGLVDSEKDAAVAKKLGLTEVDSMYVFKGDEVIEYDGEFSADTIVEFLLDVLE
[0111] [Sequence No. 2] CSQ domain 2 amino acid sequence
[0112] DPVELIEGERELQAFENIEDEIKLIGYFKSKDSEHYKAFEDAAEEFHPYIPFFATFDSKVAKKLTLKLNEIDFYEAFMEEPVTIPDKPNSEEEIVNFVEEHRRS
[0113] [Sequence No. 3] CSQ domain 3 amino acid sequence
[0114] TLRKLKPESMYETWEDDMDGIHIVAFAEEADPDGFEFLETLKAVAQDNTENPDLSIIWIDPDDFPLLVPYWEKTFDIDLSAPQIGVVNVTDADSVWMEMDDEEDLPSAEELEDWLEDVLEGEINTEDDDDDDDDD
[0115] [Sequence No. 4] Amino acid sequence of CSQ domain 1 and 2
[0116] QEGLDFPEYDGVDRVINVNAKNYKNVFKKYEVLALLYHEPPEDDKASQRQFEMEELILELAAQVLEDKGVGFGLVDSEKDAAVAKKLGLTEVDSMYVFKGDEVIEYDGEFSADT IVEFLLDVLEDPVELIEGERELQAFENIEDEIKLIGYFKSKDSEHYKAFEDAEEEFHPYIPFFATFDSKVAKKLTLKLNEIDFYEAFMEEPVTIPDKPNSEEEIVNFVEEHRRS
[0117] [Sequence No. 5] CSQ domain 1 and 3 amino acid sequences
[0118] QEGLDFPEYDGVDRVINVNAKNYKNVFKKYEVLALLYHEPPEDDKASQRQFEMEELILELAAQVLEDKGVGFGLVDSEKDAAVAKKLGLTEVDSMYVFKGDEVIEYDGEFSADTIVEFLLDVLETLRKL KPESMYETWEDDMDGIHIVAFAEEADPDGFEFLETLKAVAQDNTENPDLSIIWIDPDDFPLLVPYWEKTFDIDLSAPQIGVVNVTDADSVWMEMDDEEDLPSAEELEDWLEDVLEGEINTEDDDDDDDDD
[0119] [Sequence No. 6] CSQ domain 2 and 3 amino acid sequences
[0120] DPVELIEGERELQAFENIEDEIKLIGYFKSKDSEHYKAFEDAAEEFHPYIPFFATFDSKVAKKLTLKLNEIDFYEAFMEEPVTIPDKPNSEEEIVNFVEEHRRSTLRKLKPESMYETWE DDMDGIHIVAFAEEADPDGFEFLETLKAVAQDNTENPDLSIIWIDPDDFPLLVPYWEKTFDIDLSAPQIGVVNVTDADSVWMEMDDEEDLPSAEELEDWLEDVLEGEINTEDDDDDDDDD
[0121] [Sequence No. 7] Full CSQ amino acid sequence
[0122] QEGLDFPEYDGVDRVINVNAKNYKNVFKKYEVLALLYHEPPEDDKASQRQFEMEELILELAAQVLEDKGVGFGLVDSEKDAAVAKKLGLTEVDSMYVFKGDEVIEYDGEFADTIVEFLLDVLEDPVELIEGERELQAFENIEDEIKLIGYFKSKDSEHYKAFEDAAEEFHPYIPFFATFDSKVAKKLTLKLNEIDFYEAFMEEPVTIPDKPNSEEEIVNFVEEHRRSTLRKLKPESMYETWEDDMDGIHIVAFAEEADPDGFEFLETLKAVAQDNTENPDLSIIWIDPDDFPLLVPYWEKTFDIDLSAPQIGVVNVTDADSVWMEMDDEEDLPSAEELEDWLEDVLEGEINTEDDDDDDD
Claims
1. A vector for expressing a target protein comprising a nucleic acid encoding a fusion protein containing a calsequestrin (CSQ) domain and a target protein, wherein A vector for expressing a target protein, characterized in that the calciquestrin domain comprises any one amino acid sequence selected from the group consisting of SEQ ID NOs 1 to 6.
2. In Paragraph 1, A vector for expressing a target protein, characterized in that the above calciquestrin domain comprises the amino acid sequence of SEQ ID NO.
1.
3. In Paragraph 1, A vector for expressing a target protein, characterized in that the above calciquestrin domain comprises the amino acid sequence of SEQ ID NO.
4.
4. In Paragraph 1, A vector for expressing a target protein, characterized in that the above calciquestrin domain comprises the amino acid sequence of SEQ ID NO.
5.
5. In Paragraph 1, A vector for expressing a target protein, characterized in that the vector further comprises a linker sequence between the calsequestrin domain and the target protein.
6. In Paragraph 5, A vector for expressing a target protein, characterized in that the above linker sequence is a GGGGS, GSGSGS, or (GGGGS)n (where n is an integer from 1 to 10) repeat sequence.
7. In Paragraph 1, A vector for expressing a target protein, characterized in that the above vector further comprises a cleavage site between the calsequestrin domain and the target protein.
8. In Paragraph 7, A vector for expressing a target protein, characterized in that the above-mentioned cleavage site is one or more selected from the group consisting of thrombin recognition sequence (LVPRGS), enterokinase recognition sequence (DDDDK), TEV protease recognition sequence (ENLYFQG) and factor Xa recognition sequence (IEGR).
9. In Paragraph 1, A vector for expressing a target protein characterized by the above target protein exhibiting a higher expression level compared to the case where SEQ ID NO. 7 is included as a fusion partner.
10. A method for producing a target protein using a calciquestrin domain comprising the following steps: (a) a step of preparing an expression vector comprising a nucleic acid encoding a fusion protein in which a calsequestrin domain and a target protein are fused through a cleavage site; (b) a step of producing a transformant by introducing the above expression vector into a host cell; (c) a step of expressing a fusion protein in which the calsequestrin domain and the target protein are fused from the transformant; (d) a step of precipitating the fusion protein from the transformant using calcium; and (e) A step of separating the target protein from the fusion protein using a hydrolytic enzyme.
11. In Paragraph 10, A method for producing a target protein, characterized in that the above calciquestrin domain comprises any one amino acid sequence selected from the group consisting of SEQ ID NOs 1 to 6.
12. In Paragraph 10 or 11, A method for producing a target protein, characterized in that the calciquestrin domain comprises the amino acid sequence of SEQ ID NO. 1, SEQ ID NO. 4, or SEQ ID NO.
5.
13. In Paragraph 10, A method for producing a target protein, characterized in that the expression vector further comprises a linker sequence between the calsequestrin domain and the target protein.
14. In Paragraph 13, A method for producing a target protein, characterized in that the above linker sequence is a repeat sequence of GGGGS, GSGSGS, or (GGGGS)n (where n is an integer from 1 to 10).
15. In Paragraph 10, A method for producing a target protein, characterized in that the expression vector further comprises a cleavage site between the calsequestrin domain and the target protein.
16. In Paragraph 15, A method for producing a target protein, characterized in that the above-mentioned cleavage site is one or more selected from the group consisting of thrombin recognition sequence (LVPRGS), enterokinase recognition sequence (DDDDK), TEV protease recognition sequence (ENLYFQG), and factor Xa recognition sequence (IEGR).
17. In Paragraph 10, A method for producing a target protein, characterized in that the host cell is one or more selected from the group consisting of Escherichia coli, Bacillus subtilis, Bacillus thuringiensis, Salmonella typhimurium, Serratia marcescens, Pseudomonas sp., yeast, insect cells, CHO cells, WI-38 cells, BHK cells, COS-7 cells, HEK293 cells, HepG2 cells, 3T3 cells, RIN cells, MDCK cells, and plant cells.
18. In Paragraph 10, A method for producing a target protein characterized by the above target protein exhibiting a higher expression level compared to the case where SEQ ID NO. 7 is included as a fusion partner.
19. In Paragraph 10, A method for producing a target protein, characterized in that the calcium in step (d) above is one or more selected from the group consisting of calcium chloride (CaCl₂), calcium sulfate (CaSO₄), calcium nitrate (Ca(NO₃)₂), and calcium acetate (Ca(CH₃COO)₂).
20. In Paragraph 10, A method for producing a target protein, characterized in that the above hydrolytic enzyme is one or more selected from the group consisting of thrombin, enterokinase, TEV protease, and factor Xa.
